Please login to the form below

Not currently logged in
Email:
Password:

AZ settles Seroquel patent case

AstraZeneca has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR in the US

AstraZeneca (AZ) has entered into a settlement agreement with Accord Health and Intas regarding patent litigation for Seroquel XR (quetiapine humarate) in the US.

AZ filed litigation against Accord following the company's submission to the US Food and Drug Administration (FDA) of an abbreviated new drug application for a generic version of the depression treatment.

As part of the agreement, AZ has granted Accord a licence to enter the US market with its generic Seroquel XR on November 1, 2016, or earlier, depending upon certain circumstances.

The drug is protected by patents and other exclusivity rights that range from March 2012 to November 2017.

Remaining Seroquel XR patent infringement litigations are ongoing.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics